Novavax Inc (NVAX)

After Hours
- Real-time Data
  • Volume:
  • Bid/Ask:
  • Day's Range:
    160.20 - 173.45

NVAX Overview

Prev. Close
Day's Range
52 wk Range
Market Cap
Dividend (Yield)
Average Volume (3m)
P/E Ratio
1-Year Change
Shares Outstanding
Next Earnings Date
10 Nov 2021
What is your sentiment on Novavax Inc?
Market is currently closed. Voting is open during market hours.

Novavax Inc News

Novavax Inc Analysis

  • Novavax Stock: Positioned for Further Rally
    • ByTipRanks-

    The COVID-19 vaccine market in developed economies is dominated by the likes of Pfizer (PFE) and Moderna (MRNA). These companies have benefitted from an early-mover...

  • Vaccine Victory Lap
    • ByTalkmarkets-

    Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday...

Technical Summary

5 Min
15 Min
Moving AveragesStrong SellStrong SellStrong SellStrong SellBuy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellSell
SummaryStrong SellStrong SellStrong SellStrong SellNeutral

Novavax Inc Company Profile

Novavax Inc Company Profile


Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Read More
  • Why NVAX director sold around 26000 shares?
    • to take profit. and buy in again at lower price.
    • Directors cant just buy and sell as they feel like. So they have pre agreed trading plans. Its just tradhy journos writing rubbish articles to sppok investors.. only motive i can see. They ate probdbly in bed with short sellers. What they usually dont make clear is that when they sell stock they also iften purchase options at the same time.
  • buy its jackpot time next stop 290
    • If the vaccination route is overtaken by a single pill it will have a negative impact for NVAX and MRNA Assuming the pill is not FDA approved can see by year end NVAX breaking through $300.
  • “We need an urgent reversal from the majority of vaccines going to high income countries, to the majority going to low income countries,” said WHO Director-General Tedros Adhanom Ghebreyesus.
    • this gonna big 300 next stop
      • Never lose faith in this stock. Gonna be the next big vax!
        • ☝🏻☝🏻☝🏻☝🏻☝🏻
          • surprise ... down for financial and another down on Monday I guess
            • Why surprise ??
          • surprise surprise... down for financials and another down on Monday I guess
            • One of the best stocks to get.. Will easily rise to 300 with the EU deal.
              • Modernas current market capitalisation is 10x that of Novavax.. inderatand they got a head start but given the results and based on the deal with EU, suggests filing for regulatory approval is imminent. Post approval novavax have a vaccine that is at least as good and also have a stage 3 flu vaccine as good or better than anything on the market. So combo flu / covid boosters = advantage novavax at current valuations.
                • 250+?
                  • Novavax unable to get approval from any country so far. Only trials that say 90% effective but no approval as production process not ironed out. Q1 approval application delayed to Q3 already. 2021 sales of vaccine in doubt.
                    • They’ve already signed purchase agreement for 270 odd mllion in developed countries and over a billion for low and middle income. So not sure sales will be an issue.
                    • Not denying that they have orders but question is one of delivery. Maybe 2022 will be when they can start but till regulatory approvals start coming later this year, they remain behind the curve of other vax providers.
                  • NEJM.ORG announce Novax is safe !!
                    • Korea Drug and Food Safety official just before confirmed again they are now pre-reviewing the clinical trial data and will rapidly proceed the approval process as soon as SK Biosciense/NVAX submit their P3 approval documents regardless of the NVAX's filing plan in Q3 for FDA, MHRA and EMA.
                      • Korean government said this morning (May 12th in Korea time) they have no change with the existing rollout and admin plans of NVAX vaccine in Korea as Korean FDA is now reviewing the NVAX's clinical trial data submitted by SK Bioscience in parallel with and/or independent of FDA, MHRA and EMA.SK Biosciense now keeps their validation (It might seem to have been completed as they said last month their validation vaccine could be used for commercial purpose.) or commercial operation going and plans to commercially rollout 30m doses of the NVAX vaccine this year and another 10m doses in the early of next year to start to provide them to Korean government from June or July of this year. Korea Ministry of Food and Drug Safety is likely to approve the NVAX jab firstly in the world in next month as Korea President, Mr. Moon announced Monday (May 10) Korea government seems to move up their jab inoculation plan which is to achieve the herd immunity by November. It seems Korea government knows something that the US P3 results would NOT be different from the UK P3 results. Let's see what will happen soon....
                        • So is there an expectation on when they will approve?
                      • dud
                        • Not sure how you work that out. Highest efficacy of all the vaccines against the original strain. Their technology also delivered the first malaria vaccine over 75 percent efficacy in a recent trial and its late stafe flu vaccine is as good or better than anything currently on the market. The only duds are the morons currently panic selling on the eve of approvals and a supply agreement with the EU.
                      • the support is coming at 140
                        • Cant understand the selloff with approvals pending. Makes no sense.
                          • Guess the Company History with failed drug research does not help. However if they get FDA approval ( late April ?)they could soar to $400 plus.
                        • Court case. Great!
                          • Please clarify - what court case ?
                        • 1.1billion vaccine deal for nvax announced this evening
                          • I bought share per 328, can I hold or sell now please advise
                            • Biden says USA will have sufficient vaccines for all adults by end May. Nvax not due for approval before early May so stock now less solid as recent sell off confirms.
                            • Roshan GuptaAre you still holding it
                            • yes..holding some for positive results
                          • The day to hit 300
                            • Starting to fet itritated by all the press releases saying although Moderna and Pfizer vaccines are more efficacious.. i might be missing somethung but did their trial not report against the initial strain... and theyve acknowledged that there caccine wont be as effective afainst the new strain... comparing apples with apples novavax on UK trials reported 95.6 percent efficacy against the original strain.. so on that comparison is it not the highest efficacy against that strain.. and the other strains are still an efficacy question mark for the others?
                              • Your comment appears contradictory. Are you saying NVAX better than, equal to or less efficient than MRNA or PFE
                              • Not sure how that is contradictory. Morderna’s and pfifers results are based on original strain. I believe their efficacy was around 94 percent and up to 90 percent respectively. Like for like against the original strajn nvax confirmed theirs to be 95.6 percent against the original strain. So not sure how thats inferior. Both moderna and pfizer have said theres would be leas effective against the new strain, but they dont have data as to what this is. Novavax does and its 89.3 percent efficacy combined strains. So sating its inferior is lazy jourbalism.
                              • Ok now clearer; got out at $325 a few days ago near ATH.May buy back if price retreats further. On paper it should be now a stronger stock than MRNA as its vaccine potential still to come ( hopefully).
                            • It can go to 300 in days or today
                              • On fire
                                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.